Although not studied in the context of breast cancer, UGP2 expression (both high and low) has been implicated in the progression of other cancers [47, 48], and our data suggest a potential uncharacterized role for UGP2 in breast cancer in the context of treatment. Here, UGP2 is linked to breast carcinoma.